Genmab drops zalutumumab

Genmab has shelved zalutumumab, a drug for squamous cell carcinoma of the head and neck, to focus on other drugs in its pipeline. The developer announced last year that it would hunt for a partner to finance costly trials of the drug, which were necessary to achieve U.S. approval. But Genmab wasn't able to find any developers to foot the bill. Article

Suggested Articles

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.

In our EuroBiotech roundup this week, Nordic Nanovector delays phase 2b readout, PPF buys big Autolus stake and Poxel shares phase 3 diabetes data.